Cytyc's Breakout Year

Cytyc Corp., which makes the ThinPrep test for cervical cancer screening, has had a breakout year. A new deal with Quest Diagnostics Inc., reimbursement from a key managed care organization, Aetna, and weaker than expected competition is driving sales and the company's stock price.

Events in the second half of 1999 put to rest any doubts people might have had about the commercialization of Cytyc Corp. 's ThinPreptest for cervical cancer screening. According to Al Kildani, an analyst with Pacific Growth Equity, people following the market were concerned about reimbursement and competition, notably from TriPath Imaging Inc. , the only other company to receive FDA approval for a liquid-based cervical cancer test (see "Smear Campaign," IN VIVO, June 1996 [A#1996800138). But TriPath's labeling for its product, which got approval in June of last year, isn't as strong as Cytyc's; moreover, it was second to market, coming out more than two years after the ThinPrep. And, in 1999, Aetna agreed to reimburse for the ThinPrep at reasonable rates, making it the last of the major insurance carriers to support the product, Kildani notes.

But Cytyc's deal with Quest Diagnostics Inc. [See Deal], doing 10 million Pap smears a year. It has agreed...

More from Leadership

Rising Leaders 2025: J&J’s June Lanoue On Working With A Cure In Mind

 
• By 

As president of US Hematology at J&J, June Lanoue's leadership approach focuses on improving patient outcomes and organizational development. Her career path demonstrates the role of curiosity and adaptability in health care advancement.

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

More from In Vivo

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

 
• By 

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By 

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy